Latest News

Overall survival after 10 years appears to be comparable regardless of whether patients 65 years or older received irradiation following surgery for low-risk, hormone receptor–positive breast cancer.
Post-Surgical Radiation Omission did not Raise Breast Cancer Distant Recurrence

March 28th 2023

Overall survival after 10 years appears to be comparable regardless of whether patients 65 years or older received irradiation following surgery for low-risk, hormone receptor–positive breast cancer.

Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.
Patritumab Deruxtecan Demonstrates Continued Activity in Breast/Lung Cancer

March 22nd 2023

Bria-IMT plus retifanlimab continues to show positive clinical outcomes in a small cohort of patients with advanced, metastatic breast cancer, according to new data from a phase 1/2 trial.
Early Data Show Ongoing Benefit of Bria-IMT in Small Breast Cancer Population

March 20th 2023

The phase 3 TORCHLIGHT study, examining toripalimab and paclitaxel, has become the first study in China to achieve positive outcomes with immunotherapy for triple-negative breast cancer.
Chinese Study Reports Promising Early Data on Toripalimab in TNBC

March 10th 2023

Patients with high-risk early breast cancer who are eligible for treatment with abemaciclib can be identified via nodal status as well as tumor size and grade.
FDA Expands Abemaciclib Approval to Include HR+ HER2– Node+ High-Risk Breast Cancer

March 3rd 2023

More News